Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in Non-Diabetic Chronic Kidney Disease
2023-506897-11-00Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Finerenone + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Mean rate of change in eGFR (total slope). Started Apr 2024; status: completed.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-506897-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506897-11-00.